Degludec insulin, with an ultra-long-action profile, has recently been approved to be commercialized, and only one study in patients with different stages of renal failure and terminal CKD has been published, showing no statistical significant differences in absorption or release profiles when compared to individuals with normal renal function. This evidence concerns the gene INS and chronic kidney disease.